ATE181359T1 - Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen - Google Patents

Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen

Info

Publication number
ATE181359T1
ATE181359T1 AT93912315T AT93912315T ATE181359T1 AT E181359 T1 ATE181359 T1 AT E181359T1 AT 93912315 T AT93912315 T AT 93912315T AT 93912315 T AT93912315 T AT 93912315T AT E181359 T1 ATE181359 T1 AT E181359T1
Authority
AT
Austria
Prior art keywords
virus
attenuated
vaccine compositions
rsv
synzytial
Prior art date
Application number
AT93912315T
Other languages
English (en)
Inventor
Brian Robert Murphy
Robert Merritt Chanock
James Earl Crowe Jr
Mark Connors
Kuo-Hom Lee Hsu
Alan Robert Davis
Michael David Lubeck
Bernard Hugh Apt N- Selling
Original Assignee
American Home Prod
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod, Us Health filed Critical American Home Prod
Application granted granted Critical
Publication of ATE181359T1 publication Critical patent/ATE181359T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
AT93912315T 1992-04-21 1993-04-20 Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen ATE181359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87274692A 1992-04-21 1992-04-21
US3994593A 1993-04-09 1993-04-09

Publications (1)

Publication Number Publication Date
ATE181359T1 true ATE181359T1 (de) 1999-07-15

Family

ID=26716607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93912315T ATE181359T1 (de) 1992-04-21 1993-04-20 Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen

Country Status (18)

Country Link
US (3) US5922326A (de)
EP (1) EP0640128B1 (de)
JP (1) JP3883202B2 (de)
KR (1) KR100257171B1 (de)
AT (1) ATE181359T1 (de)
AU (1) AU683840B2 (de)
CA (1) CA2118509C (de)
DE (1) DE69325370T2 (de)
DK (1) DK0640128T3 (de)
ES (1) ES2132233T3 (de)
GR (1) GR3031208T3 (de)
HU (1) HU220189B (de)
IL (1) IL105456A (de)
MX (1) MX9302278A (de)
NZ (1) NZ252857A (de)
RU (1) RU2139729C1 (de)
UA (1) UA41315C2 (de)
WO (1) WO1993021310A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
TW275632B (de) * 1992-04-21 1996-05-11 American Cyanamid Co
EP0714306B1 (de) 1993-08-06 1998-03-25 Connaught Laboratories Limited Inaktivierte respiratorische synzytial-virus-impfstoffe
US7223410B1 (en) 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
JPH11512609A (ja) 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性RSウイルス(respiratory syncytial virus)の生産
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
EP0917592A4 (de) * 1996-04-04 2002-04-24 Univ Michigan Abgeschwaechter rsv
EP0936921B1 (de) * 1996-07-12 2003-03-19 Aventis Pasteur Limited Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
JP4413999B2 (ja) * 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
BR9712138A (pt) * 1996-09-27 2000-01-18 American Cyanamid Co Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6579528B1 (en) 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
CA2369200A1 (en) 1999-04-13 2000-10-19 Peter L. Collins Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
WO2001004335A2 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Human-bovine chimeric respiratory syncytial virus vaccines
WO2001074386A2 (en) 2000-04-03 2001-10-11 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
JP2005508927A (ja) * 2001-09-28 2005-04-07 ユニバーシティ オブ サウス フロリダ Rsv遺伝子発現ワクチン
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
EP1572108A4 (de) * 2002-09-27 2008-09-17 Medimmune Vaccines Inc Funktionale mutationen des rsv (respiratory syncytial virus)
US7687240B2 (en) * 2003-03-18 2010-03-30 Wyeth Holdings Corporation Process for increasing RSV surface glycoprotein yields using a mutant strain of RSV
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
EP2581093B1 (de) * 2003-06-16 2015-03-18 MedImmune, LLC Influenza-Hämagglutinin- und Neuraminidase-Varianten
DK1701738T3 (en) * 2003-12-17 2015-03-30 Wyeth Llc Process for preparing storage-stable RSV compositions
DE602004027537D1 (de) * 2003-12-23 2010-07-15 Medimmune Inc
AU2005248377B2 (en) * 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US7601356B2 (en) * 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2069484B1 (de) * 2007-06-18 2014-08-13 MedImmune, LLC Influenza-B-Viruses mit verändertem Hämagglutininpolypeptid
WO2009012155A2 (en) * 2007-07-13 2009-01-22 Medimmune, Llc Preparation of negative-stranded rna viruses by electroporation
MX2011000437A (es) 2008-07-11 2012-03-07 Medimmune Llc Variantes de hemaglutinina y neuramnidasa de influenza.
CN102361649A (zh) 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
US9017694B2 (en) 2011-10-07 2015-04-28 Medimmune, Llc Swine influenza hemagglutinin variants
WO2013154728A1 (en) 2012-04-13 2013-10-17 The United States Of America , As Represented By The Secretary, Department Of Health And Human Services Genetically stable live attenuated respiratory syncytial virus vaccine and its production
CA2902560A1 (en) 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
EP2970981B1 (de) 2013-03-14 2020-10-28 Emory University Rekombinante rsv mit stillen mutationen, impfstoffe und zugehörige verfahren
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof

Also Published As

Publication number Publication date
HUT69992A (en) 1995-09-28
DK0640128T3 (da) 1999-11-22
ES2132233T3 (es) 1999-08-16
US5922326A (en) 1999-07-13
AU4290793A (en) 1993-11-18
IL105456A0 (en) 1993-08-18
EP0640128B1 (de) 1999-06-16
IL105456A (en) 1996-12-05
CA2118509C (en) 2009-05-19
RU2139729C1 (ru) 1999-10-20
NZ252857A (en) 1997-06-24
EP0640128A1 (de) 1995-03-01
US6284254B1 (en) 2001-09-04
US5882651A (en) 1999-03-16
WO1993021310A1 (en) 1993-10-28
KR100257171B1 (ko) 2000-05-15
HU220189B (hu) 2001-11-28
AU683840B2 (en) 1997-11-27
GR3031208T3 (en) 1999-12-31
JP3883202B2 (ja) 2007-02-21
KR950701382A (ko) 1995-03-23
UA41315C2 (uk) 2001-09-17
CA2118509A1 (en) 1993-10-28
DE69325370T2 (de) 1999-10-14
MX9302278A (es) 1994-07-29
JPH07505891A (ja) 1995-06-29
RU94045898A (ru) 1996-09-20
HU9403023D0 (en) 1994-12-28
DE69325370D1 (de) 1999-07-22

Similar Documents

Publication Publication Date Title
ATE181359T1 (de) Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen
CA2339089A1 (en) Cold-adapted equine influenza viruses
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
BRPI9710363B1 (pt) partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
DK0869814T3 (da) Stabilisatorer til levende vacciner
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
NO20002605L (no) Sferoider, fremstillingsmetode og farmasøytiske sammensetninger
GB9306731D0 (en) Vaccines
DK22389A (da) Fremgangsmaade og middel til beskyttelse mod sygdomme foraarsaget af mikroorganismer, navnlig mycoplasma
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
AU4930001A (en) Cold-adapted equine influenza viruses
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO2003049670A3 (en) Adjuvant formulations for bacterial and virus vaccines and method of making same
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
ES2055610T3 (es) Vacuna contra hrsv.
WO2003006645A3 (en) Method and composition for inhibiting heparanase activity
NO982854L (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee